
EVAX Stock Forecast & Price Target
EVAX Analyst Ratings
Bulls say
Evaxion is a clinical-stage TechBio company that has developed a proprietary AI platform, AI-Immunology, which has shown promise in developing novel vaccines for both oncology and infectious diseases. The company's pivot into autoimmune disease indications is a strategic move that could potentially expand their market and revenue potential. Additionally, their development of off-the-shelf therapies, such as EVX-04, may address scalability and time-to-treatment concerns and attract investors.
Bears say
Evaxion is a clinical-stage TechBio company that has a promising AI platform and a pipeline of novel personalized vaccines for cancer and infectious diseases. However, the group's financials may be suffering as their lead personalized neoantigen vaccine, EVX-01, had a low overall response rate of 75% and a relatively small sample size of patients (16) in their two-year efficacy results. Investors should closely monitor the company's next major clinical update, which includes three-year efficacy data.
This aggregate rating is based on analysts' research of Evaxion Biotech A/S and is not a guaranteed prediction by Public.com or investment advice.
EVAX Analyst Forecast & Price Prediction
Start investing in EVAX
Order type
Buy in
Order amount
Est. shares
0 shares